Cosciens Biopharma Inc (CSCIF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 10,757 | -10,358 | -8,175 | -6,356 | -3,655 |
| Depreciation Amortization | 341 | 1,075 | 787 | 498 | 300 |
| Accounts receivable | -1,009 | 1,145 | 2,203 | 494 | 1,101 |
| Other Working Capital | -1,419 | 292 | -147 | -1,098 | 1,327 |
| Other Operating Activity | -10,847 | -627 | -1,671 | 135 | -953 |
| Operating Cash Flow | $-2,177 | $-8,473 | $-7,003 | $-6,327 | $-1,880 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 7 | -462 | -655 | -659 | -611 |
| Net Acquisitions | -30 | N/A | N/A | N/A | N/A |
| Other Investing Activity | 0 | 4 | -4 | -4 | -4 |
| Investing Cash Flow | $-23 | $-458 | $-659 | $-663 | $-615 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | -82 | -407 | -392 | -307 | -200 |
| Financing Cash Flow | $-82 | $-407 | $-392 | $-307 | $-200 |
| Exchange Rate Effect | -20 | 252 | 185 | 237 | 60 |
| Beginning Cash Position | 7,307 | 16,393 | 16,393 | 16,393 | 16,393 |
| End Cash Position | 5,005 | 7,307 | 8,524 | 9,333 | 13,758 |
| Net Cash Flow | $-2,302 | $-9,086 | $-7,869 | $-7,060 | $-2,635 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,177 | -8,473 | -7,003 | -6,327 | -1,880 |
| Capital Expenditure | -2 | -706 | -660 | -664 | -615 |
| Free Cash Flow | -2,179 | -9,179 | -7,663 | -6,991 | -2,495 |